The global Chronic Liver Diseases Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Chronic Liver Diseases Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Liver Diseases Therapeutics.

Report Scope

The Chronic Liver Diseases Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Liver Diseases Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Chronic Liver Diseases Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Chronic Liver Diseases Therapeutics Market Report

Report Metric	Details
Report Name	Chronic Liver Diseases Therapeutics Market
CAGR	5%
Segment by Type	Chemotherapy Drugs Targeted Therapy Vaccines Antiviral Drugs Immunoglobulins Corticosteroids Others
Segment by Application	Hospital Pharmacies Retail Pharmacies Online Pharmacies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Astellas Pharma, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, F. Hoffmann-La Roche, Merck, Novartis, Sanofi, Pfizer, Takeda Pharmaceutical, Bausch Health, Theratechnologies, Alnylam Pharmaceuticals, Protagonist Therapeutics, Dicerna Pharmaceuticals, Endo International, Provectus Biopharmaceuticals, MAX BioPharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Liver Diseases Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Chronic Liver Diseases Therapeutics Market report?

Ans: The main players in the Chronic Liver Diseases Therapeutics Market are Astellas Pharma, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, F. Hoffmann-La Roche, Merck, Novartis, Sanofi, Pfizer, Takeda Pharmaceutical, Bausch Health, Theratechnologies, Alnylam Pharmaceuticals, Protagonist Therapeutics, Dicerna Pharmaceuticals, Endo International, Provectus Biopharmaceuticals, MAX BioPharma

What are the Application segmentation covered in the Chronic Liver Diseases Therapeutics Market report?

Ans: The Applications covered in the Chronic Liver Diseases Therapeutics Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Chronic Liver Diseases Therapeutics Market report?

Ans: The Types covered in the Chronic Liver Diseases Therapeutics Market report are Chemotherapy Drugs, Targeted Therapy, Vaccines, Antiviral Drugs, Immunoglobulins, Corticosteroids, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Chronic Liver Diseases Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Chemotherapy Drugs

1.2.3 Targeted Therapy

1.2.4 Vaccines

1.2.5 Antiviral Drugs

1.2.6 Immunoglobulins

1.2.7 Corticosteroids

1.2.8 Others

1.3 Market by Application

1.3.1 Global Chronic Liver Diseases Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Chronic Liver Diseases Therapeutics Market Perspective (2019-2030)

2.2 Chronic Liver Diseases Therapeutics Growth Trends by Region

2.2.1 Global Chronic Liver Diseases Therapeutics Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Chronic Liver Diseases Therapeutics Historic Market Size by Region (2019-2024)

2.2.3 Chronic Liver Diseases Therapeutics Forecasted Market Size by Region (2025-2030)

2.3 Chronic Liver Diseases Therapeutics Market Dynamics

2.3.1 Chronic Liver Diseases Therapeutics Industry Trends

2.3.2 Chronic Liver Diseases Therapeutics Market Drivers

2.3.3 Chronic Liver Diseases Therapeutics Market Challenges

2.3.4 Chronic Liver Diseases Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Chronic Liver Diseases Therapeutics Players by Revenue

3.1.1 Global Top Chronic Liver Diseases Therapeutics Players by Revenue (2019-2024)

3.1.2 Global Chronic Liver Diseases Therapeutics Revenue Market Share by Players (2019-2024)

3.2 Global Chronic Liver Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Chronic Liver Diseases Therapeutics Revenue

3.4 Global Chronic Liver Diseases Therapeutics Market Concentration Ratio

3.4.1 Global Chronic Liver Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Chronic Liver Diseases Therapeutics Revenue in 2023

3.5 Chronic Liver Diseases Therapeutics Key Players Head office and Area Served

3.6 Key Players Chronic Liver Diseases Therapeutics Product Solution and Service

3.7 Date of Enter into Chronic Liver Diseases Therapeutics Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Chronic Liver Diseases Therapeutics Breakdown Data by Type

4.1 Global Chronic Liver Diseases Therapeutics Historic Market Size by Type (2019-2024)

4.2 Global Chronic Liver Diseases Therapeutics Forecasted Market Size by Type (2025-2030)

5 Chronic Liver Diseases Therapeutics Breakdown Data by Application

5.1 Global Chronic Liver Diseases Therapeutics Historic Market Size by Application (2019-2024)

5.2 Global Chronic Liver Diseases Therapeutics Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Chronic Liver Diseases Therapeutics Market Size (2019-2030)

6.2 North America Chronic Liver Diseases Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Chronic Liver Diseases Therapeutics Market Size by Country (2019-2024)

6.4 North America Chronic Liver Diseases Therapeutics Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Chronic Liver Diseases Therapeutics Market Size (2019-2030)

7.2 Europe Chronic Liver Diseases Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Chronic Liver Diseases Therapeutics Market Size by Country (2019-2024)

7.4 Europe Chronic Liver Diseases Therapeutics Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Chronic Liver Diseases Therapeutics Market Size (2019-2030)

8.2 Asia-Pacific Chronic Liver Diseases Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Chronic Liver Diseases Therapeutics Market Size by Region (2019-2024)

8.4 Asia-Pacific Chronic Liver Diseases Therapeutics Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Chronic Liver Diseases Therapeutics Market Size (2019-2030)

9.2 Latin America Chronic Liver Diseases Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Chronic Liver Diseases Therapeutics Market Size by Country (2019-2024)

9.4 Latin America Chronic Liver Diseases Therapeutics Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Chronic Liver Diseases Therapeutics Market Size (2019-2030)

10.2 Middle East & Africa Chronic Liver Diseases Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Chronic Liver Diseases Therapeutics Market Size by Country (2019-2024)

10.4 Middle East & Africa Chronic Liver Diseases Therapeutics Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Astellas Pharma

11.1.1 Astellas Pharma Company Detail

11.1.2 Astellas Pharma Business Overview

11.1.3 Astellas Pharma Chronic Liver Diseases Therapeutics Introduction

11.1.4 Astellas Pharma Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.1.5 Astellas Pharma Recent Development

11.2 Bristol-Myers Squibb

11.2.1 Bristol-Myers Squibb Company Detail

11.2.2 Bristol-Myers Squibb Business Overview

11.2.3 Bristol-Myers Squibb Chronic Liver Diseases Therapeutics Introduction

11.2.4 Bristol-Myers Squibb Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.2.5 Bristol-Myers Squibb Recent Development

11.3 Gilead Sciences

11.3.1 Gilead Sciences Company Detail

11.3.2 Gilead Sciences Business Overview

11.3.3 Gilead Sciences Chronic Liver Diseases Therapeutics Introduction

11.3.4 Gilead Sciences Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.3.5 Gilead Sciences Recent Development

11.4 GlaxoSmithKline

11.4.1 GlaxoSmithKline Company Detail

11.4.2 GlaxoSmithKline Business Overview

11.4.3 GlaxoSmithKline Chronic Liver Diseases Therapeutics Introduction

11.4.4 GlaxoSmithKline Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.4.5 GlaxoSmithKline Recent Development

11.5 F. Hoffmann-La Roche

11.5.1 F. Hoffmann-La Roche Company Detail

11.5.2 F. Hoffmann-La Roche Business Overview

11.5.3 F. Hoffmann-La Roche Chronic Liver Diseases Therapeutics Introduction

11.5.4 F. Hoffmann-La Roche Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.5.5 F. Hoffmann-La Roche Recent Development

11.6 Merck

11.6.1 Merck Company Detail

11.6.2 Merck Business Overview

11.6.3 Merck Chronic Liver Diseases Therapeutics Introduction

11.6.4 Merck Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.6.5 Merck Recent Development

11.7 Novartis

11.7.1 Novartis Company Detail

11.7.2 Novartis Business Overview

11.7.3 Novartis Chronic Liver Diseases Therapeutics Introduction

11.7.4 Novartis Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.7.5 Novartis Recent Development

11.8 Sanofi

11.8.1 Sanofi Company Detail

11.8.2 Sanofi Business Overview

11.8.3 Sanofi Chronic Liver Diseases Therapeutics Introduction

11.8.4 Sanofi Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.8.5 Sanofi Recent Development

11.9 Pfizer

11.9.1 Pfizer Company Detail

11.9.2 Pfizer Business Overview

11.9.3 Pfizer Chronic Liver Diseases Therapeutics Introduction

11.9.4 Pfizer Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.9.5 Pfizer Recent Development

11.10 Takeda Pharmaceutical

11.10.1 Takeda Pharmaceutical Company Detail

11.10.2 Takeda Pharmaceutical Business Overview

11.10.3 Takeda Pharmaceutical Chronic Liver Diseases Therapeutics Introduction

11.10.4 Takeda Pharmaceutical Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.10.5 Takeda Pharmaceutical Recent Development

11.11 Bausch Health

11.11.1 Bausch Health Company Detail

11.11.2 Bausch Health Business Overview

11.11.3 Bausch Health Chronic Liver Diseases Therapeutics Introduction

11.11.4 Bausch Health Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.11.5 Bausch Health Recent Development

11.12 Theratechnologies

11.12.1 Theratechnologies Company Detail

11.12.2 Theratechnologies Business Overview

11.12.3 Theratechnologies Chronic Liver Diseases Therapeutics Introduction

11.12.4 Theratechnologies Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.12.5 Theratechnologies Recent Development

11.13 Alnylam Pharmaceuticals

11.13.1 Alnylam Pharmaceuticals Company Detail

11.13.2 Alnylam Pharmaceuticals Business Overview

11.13.3 Alnylam Pharmaceuticals Chronic Liver Diseases Therapeutics Introduction

11.13.4 Alnylam Pharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.13.5 Alnylam Pharmaceuticals Recent Development

11.14 Protagonist Therapeutics

11.14.1 Protagonist Therapeutics Company Detail

11.14.2 Protagonist Therapeutics Business Overview

11.14.3 Protagonist Therapeutics Chronic Liver Diseases Therapeutics Introduction

11.14.4 Protagonist Therapeutics Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.14.5 Protagonist Therapeutics Recent Development

11.15 Dicerna Pharmaceuticals

11.15.1 Dicerna Pharmaceuticals Company Detail

11.15.2 Dicerna Pharmaceuticals Business Overview

11.15.3 Dicerna Pharmaceuticals Chronic Liver Diseases Therapeutics Introduction

11.15.4 Dicerna Pharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.15.5 Dicerna Pharmaceuticals Recent Development

11.16 Endo International

11.16.1 Endo International Company Detail

11.16.2 Endo International Business Overview

11.16.3 Endo International Chronic Liver Diseases Therapeutics Introduction

11.16.4 Endo International Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.16.5 Endo International Recent Development

11.17 Provectus Biopharmaceuticals

11.17.1 Provectus Biopharmaceuticals Company Detail

11.17.2 Provectus Biopharmaceuticals Business Overview

11.17.3 Provectus Biopharmaceuticals Chronic Liver Diseases Therapeutics Introduction

11.17.4 Provectus Biopharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.17.5 Provectus Biopharmaceuticals Recent Development

11.18 MAX BioPharma

11.18.1 MAX BioPharma Company Detail

11.18.2 MAX BioPharma Business Overview

11.18.3 MAX BioPharma Chronic Liver Diseases Therapeutics Introduction

11.18.4 MAX BioPharma Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)

11.18.5 MAX BioPharma Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Takeda Pharmaceutical

Bausch Health

Theratechnologies

Alnylam Pharmaceuticals

Protagonist Therapeutics

Dicerna Pharmaceuticals

Endo International

Provectus Biopharmaceuticals

MAX BioPharma

List of Tables

Table 1. Global Chronic Liver Diseases Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Chemotherapy Drugs

Table 3. Key Players of Targeted Therapy

Table 4. Key Players of Vaccines

Table 5. Key Players of Antiviral Drugs

Table 6. Key Players of Immunoglobulins

Table 7. Key Players of Corticosteroids

Table 8. Key Players of Others

Table 9. Global Chronic Liver Diseases Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 10. Global Chronic Liver Diseases Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 11. Global Chronic Liver Diseases Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 12. Global Chronic Liver Diseases Therapeutics Market Share by Region (2019-2024)

Table 13. Global Chronic Liver Diseases Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 14. Global Chronic Liver Diseases Therapeutics Market Share by Region (2025-2030)

Table 15. Chronic Liver Diseases Therapeutics Market Trends

Table 16. Chronic Liver Diseases Therapeutics Market Drivers

Table 17. Chronic Liver Diseases Therapeutics Market Challenges

Table 18. Chronic Liver Diseases Therapeutics Market Restraints

Table 19. Global Chronic Liver Diseases Therapeutics Revenue by Players (2019-2024) & (US$ Million)

Table 20. Global Chronic Liver Diseases Therapeutics Market Share by Players (2019-2024)

Table 21. Global Top Chronic Liver Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Liver Diseases Therapeutics as of 2023)

Table 22. Ranking of Global Top Chronic Liver Diseases Therapeutics Companies by Revenue (US$ Million) in 2023

Table 23. Global 5 Largest Players Market Share by Chronic Liver Diseases Therapeutics Revenue (CR5 and HHI) & (2019-2024)

Table 24. Key Players Headquarters and Area Served

Table 25. Key Players Chronic Liver Diseases Therapeutics Product Solution and Service

Table 26. Date of Enter into Chronic Liver Diseases Therapeutics Market

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Chronic Liver Diseases Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 29. Global Chronic Liver Diseases Therapeutics Revenue Market Share by Type (2019-2024)

Table 30. Global Chronic Liver Diseases Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 31. Global Chronic Liver Diseases Therapeutics Revenue Market Share by Type (2025-2030)

Table 32. Global Chronic Liver Diseases Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 33. Global Chronic Liver Diseases Therapeutics Revenue Market Share by Application (2019-2024)

Table 34. Global Chronic Liver Diseases Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 35. Global Chronic Liver Diseases Therapeutics Revenue Market Share by Application (2025-2030)

Table 36. North America Chronic Liver Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 37. North America Chronic Liver Diseases Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 38. North America Chronic Liver Diseases Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 39. Europe Chronic Liver Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 40. Europe Chronic Liver Diseases Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 41. Europe Chronic Liver Diseases Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 42. Asia-Pacific Chronic Liver Diseases Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 43. Asia-Pacific Chronic Liver Diseases Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 44. Asia-Pacific Chronic Liver Diseases Therapeutics Market Size by Region (2025-2030) & (US$ Million)

Table 45. Latin America Chronic Liver Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 46. Latin America Chronic Liver Diseases Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 47. Latin America Chronic Liver Diseases Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 48. Middle East & Africa Chronic Liver Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 49. Middle East & Africa Chronic Liver Diseases Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 50. Middle East & Africa Chronic Liver Diseases Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 51. Astellas Pharma Company Detail

Table 52. Astellas Pharma Business Overview

Table 53. Astellas Pharma Chronic Liver Diseases Therapeutics Product

Table 54. Astellas Pharma Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 55. Astellas Pharma Recent Development

Table 56. Bristol-Myers Squibb Company Detail

Table 57. Bristol-Myers Squibb Business Overview

Table 58. Bristol-Myers Squibb Chronic Liver Diseases Therapeutics Product

Table 59. Bristol-Myers Squibb Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 60. Bristol-Myers Squibb Recent Development

Table 61. Gilead Sciences Company Detail

Table 62. Gilead Sciences Business Overview

Table 63. Gilead Sciences Chronic Liver Diseases Therapeutics Product

Table 64. Gilead Sciences Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 65. Gilead Sciences Recent Development

Table 66. GlaxoSmithKline Company Detail

Table 67. GlaxoSmithKline Business Overview

Table 68. GlaxoSmithKline Chronic Liver Diseases Therapeutics Product

Table 69. GlaxoSmithKline Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 70. GlaxoSmithKline Recent Development

Table 71. F. Hoffmann-La Roche Company Detail

Table 72. F. Hoffmann-La Roche Business Overview

Table 73. F. Hoffmann-La Roche Chronic Liver Diseases Therapeutics Product

Table 74. F. Hoffmann-La Roche Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 75. F. Hoffmann-La Roche Recent Development

Table 76. Merck Company Detail

Table 77. Merck Business Overview

Table 78. Merck Chronic Liver Diseases Therapeutics Product

Table 79. Merck Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 80. Merck Recent Development

Table 81. Novartis Company Detail

Table 82. Novartis Business Overview

Table 83. Novartis Chronic Liver Diseases Therapeutics Product

Table 84. Novartis Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 85. Novartis Recent Development

Table 86. Sanofi Company Detail

Table 87. Sanofi Business Overview

Table 88. Sanofi Chronic Liver Diseases Therapeutics Product

Table 89. Sanofi Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 90. Sanofi Recent Development

Table 91. Pfizer Company Detail

Table 92. Pfizer Business Overview

Table 93. Pfizer Chronic Liver Diseases Therapeutics Product

Table 94. Pfizer Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 95. Pfizer Recent Development

Table 96. Takeda Pharmaceutical Company Detail

Table 97. Takeda Pharmaceutical Business Overview

Table 98. Takeda Pharmaceutical Chronic Liver Diseases Therapeutics Product

Table 99. Takeda Pharmaceutical Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 100. Takeda Pharmaceutical Recent Development

Table 101. Bausch Health Company Detail

Table 102. Bausch Health Business Overview

Table 103. Bausch Health Chronic Liver Diseases Therapeutics Product

Table 104. Bausch Health Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 105. Bausch Health Recent Development

Table 106. Theratechnologies Company Detail

Table 107. Theratechnologies Business Overview

Table 108. Theratechnologies Chronic Liver Diseases Therapeutics Product

Table 109. Theratechnologies Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 110. Theratechnologies Recent Development

Table 111. Alnylam Pharmaceuticals Company Detail

Table 112. Alnylam Pharmaceuticals Business Overview

Table 113. Alnylam Pharmaceuticals Chronic Liver Diseases Therapeutics Product

Table 114. Alnylam Pharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 115. Alnylam Pharmaceuticals Recent Development

Table 116. Protagonist Therapeutics Company Detail

Table 117. Protagonist Therapeutics Business Overview

Table 118. Protagonist Therapeutics Chronic Liver Diseases Therapeutics Product

Table 119. Protagonist Therapeutics Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 120. Protagonist Therapeutics Recent Development

Table 121. Dicerna Pharmaceuticals Company Detail

Table 122. Dicerna Pharmaceuticals Business Overview

Table 123. Dicerna Pharmaceuticals Chronic Liver Diseases Therapeutics Product

Table 124. Dicerna Pharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 125. Dicerna Pharmaceuticals Recent Development

Table 126. Endo International Company Detail

Table 127. Endo International Business Overview

Table 128. Endo International Chronic Liver Diseases Therapeutics Product

Table 129. Endo International Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 130. Endo International Recent Development

Table 131. Provectus Biopharmaceuticals Company Detail

Table 132. Provectus Biopharmaceuticals Business Overview

Table 133. Provectus Biopharmaceuticals Chronic Liver Diseases Therapeutics Product

Table 134. Provectus Biopharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 135. Provectus Biopharmaceuticals Recent Development

Table 136. MAX BioPharma Company Detail

Table 137. MAX BioPharma Business Overview

Table 138. MAX BioPharma Chronic Liver Diseases Therapeutics Product

Table 139. MAX BioPharma Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)

Table 140. MAX BioPharma Recent Development

Table 141. Research Programs/Design for This Report

Table 142. Key Data Information from Secondary Sources

Table 143. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Chronic Liver Diseases Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Chronic Liver Diseases Therapeutics Market Share by Type: 2023 VS 2030

Figure 3. Chemotherapy Drugs Features

Figure 4. Targeted Therapy Features

Figure 5. Vaccines Features

Figure 6. Antiviral Drugs Features

Figure 7. Immunoglobulins Features

Figure 8. Corticosteroids Features

Figure 9. Others Features

Figure 10. Global Chronic Liver Diseases Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 11. Global Chronic Liver Diseases Therapeutics Market Share by Application: 2023 VS 2030

Figure 12. Hospital Pharmacies Case Studies

Figure 13. Retail Pharmacies Case Studies

Figure 14. Online Pharmacies Case Studies

Figure 15. Chronic Liver Diseases Therapeutics Report Years Considered

Figure 16. Global Chronic Liver Diseases Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 17. Global Chronic Liver Diseases Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 18. Global Chronic Liver Diseases Therapeutics Market Share by Region: 2023 VS 2030

Figure 19. Global Chronic Liver Diseases Therapeutics Market Share by Players in 2023

Figure 20. Global Top Chronic Liver Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Liver Diseases Therapeutics as of 2023)

Figure 21. The Top 10 and 5 Players Market Share by Chronic Liver Diseases Therapeutics Revenue in 2023

Figure 22. North America Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. North America Chronic Liver Diseases Therapeutics Market Share by Country (2019-2030)

Figure 24. United States Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Canada Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Europe Chronic Liver Diseases Therapeutics Market Share by Country (2019-2030)

Figure 28. Germany Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. France Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. U.K. Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Italy Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Russia Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Nordic Countries Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Asia-Pacific Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Asia-Pacific Chronic Liver Diseases Therapeutics Market Share by Region (2019-2030)

Figure 36. China Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Japan Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. South Korea Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Southeast Asia Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. India Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Australia Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Latin America Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Latin America Chronic Liver Diseases Therapeutics Market Share by Country (2019-2030)

Figure 44. Mexico Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Brazil Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Middle East & Africa Chronic Liver Diseases Therapeutics Market Share by Country (2019-2030)

Figure 48. Turkey Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Saudi Arabia Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 50. Astellas Pharma Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 51. Bristol-Myers Squibb Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 52. Gilead Sciences Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 53. GlaxoSmithKline Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 54. F. Hoffmann-La Roche Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 55. Merck Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 56. Novartis Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 57. Sanofi Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 58. Pfizer Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 59. Takeda Pharmaceutical Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 60. Bausch Health Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 61. Theratechnologies Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 62. Alnylam Pharmaceuticals Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 63. Protagonist Therapeutics Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 64. Dicerna Pharmaceuticals Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 65. Endo International Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 66. Provectus Biopharmaceuticals Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 67. MAX BioPharma Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions